Lexicon Pharmaceuticals Stock Today

LXRX Stock  USD 2.40  0.21  9.59%   

Performance

10 of 100

 
Low
 
High
OK

Odds Of Distress

Over 68

 
100  
 
Zero
Quite High
Lexicon Pharmaceuticals is trading at 2.40 as of the 29th of March 2024; that is 9.59 percent increase since the beginning of the trading day. The stock's open price was 2.19. Lexicon Pharmaceuticals has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for Lexicon Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of April 2022 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of April 2000
Category
Healthcare
Classification
Health Care
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 246.24 M outstanding shares of which 21.35 M shares are now shorted by private and institutional investors with about 3.31 trading days to cover. More on Lexicon Pharmaceuticals

Moving together with Lexicon Stock

  0.75EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Lexicon Stock

  0.7VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.64MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.58MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.47KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.46MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
  0.45VAXX Vaxxinity Financial Report 14th of May 2024 PairCorr
  0.44MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr

Lexicon Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lexicon Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lexicon Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorLonnel Coats
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Lexicon Pharmaceuticals report their recommendations after researching Lexicon Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Lexicon Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Lexicon Pharmaceuticals. The Lexicon consensus assessment is calculated by taking the average forecast from all of the analysts covering Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Lexicon Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexicon Pharmaceuticals' financial leverage. It provides some insight into what part of Lexicon Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Lexicon Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Lexicon Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Lexicon Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 104.77 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Lexicon Pharmaceuticals has a current ratio of 3.77, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lexicon Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lexicon Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lexicon Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lexicon to invest in growth at high rates of return. When we think about Lexicon Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

End Period Cash Flow

21.34 Million
Lexicon Pharmaceuticals (LXRX) is traded on NASDAQ Exchange in USA. It is located in 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381 and employs 285 people. Lexicon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 539.26 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lexicon Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Lexicon Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Lexicon Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 246.24 M outstanding shares of which 21.35 M shares are now shorted by private and institutional investors with about 3.31 trading days to cover. Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (161.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Lexicon Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Lexicon Pharmaceuticals holds a total of 246.24 Million outstanding shares. The majority of Lexicon Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexicon Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexicon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Lexicon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Lexicon Ownership Details

Lexicon Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Lexicon Pharmaceuticals jumping above the current price in 90 days from now is about 28.93%. The Lexicon Pharmaceuticals probability density function shows the probability of Lexicon Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.363. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Lexicon Pharmaceuticals will likely underperform. Additionally, lexicon Pharmaceuticals has an alpha of 0.8943, implying that it can generate a 0.89 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 2.4HorizonTargetOdds Above 2.4
71.00%90 days
 2.40 
28.93%
Based on a normal probability distribution, the odds of Lexicon Pharmaceuticals to move above the current price in 90 days from now is about 28.93 (This Lexicon Pharmaceuticals probability density function shows the probability of Lexicon Stock to fall within a particular range of prices over 90 days) .

Lexicon Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Lexicon Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lexicon Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lexicon Pharmaceuticals' value.
InstituionRecorded OnShares
Pinnacle Associates Inc2023-12-31
1.7 M
Millennium Management Llc2023-12-31
1.6 M
Morgan Stanley - Brokerage Accounts2023-12-31
917.7 K
Charles Schwab Investment Management Inc2023-12-31
864.2 K
Northern Trust Corp2023-12-31
859.6 K
D. E. Shaw & Co Lp2023-09-30
784.1 K
Gsa Capital Partners Llp2023-12-31
780.1 K
Alyeska Investment Group, L.p.2023-09-30
509.5 K
Goldman Sachs Group Inc2023-12-31
470.7 K
Artal Group S A2023-12-31
117.6 M
Bvf Inc2023-09-30
20 M
View Lexicon Pharmaceuticals Diagnostics

Lexicon Pharmaceuticals Historical Income Statement

Lexicon Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Lexicon's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lexicon Pharmaceuticals revenue and expense. Lexicon Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Lexicon Pharmaceuticals' Interest Expense is fairly stable compared to the past year. Research Development is likely to rise to about 97.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024. View More Fundamentals

Lexicon Stock Against Markets

Picking the right benchmark for Lexicon Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lexicon Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lexicon Pharmaceuticals is critical whether you are bullish or bearish towards Lexicon Pharmaceuticals at a given time. Please also check how Lexicon Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lexicon Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module

Lexicon Pharmaceuticals Corporate Directors

Lexicon Pharmaceuticals corporate directors refer to members of a Lexicon Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Lexicon Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Lexicon Pharmaceuticals' board members must vote for the resolution. The Lexicon Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Robert LefkowitzIndependent DirectorProfile
Christopher SobeckiIndependent DirectorProfile
Alan NiesIndependent DirectorProfile
Frank PalantoniIndependent DirectorProfile

How to buy Lexicon Stock?

Before investing in Lexicon Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Lexicon Pharmaceuticals. To buy Lexicon Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Lexicon Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Lexicon Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Lexicon Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Lexicon Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Lexicon Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Already Invested in Lexicon Pharmaceuticals?

The danger of trading Lexicon Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lexicon Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lexicon Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lexicon Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.80)
Revenue Per Share
0.005
Quarterly Revenue Growth
24.071
Return On Assets
(0.51)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.